凉血散瘀汤联合胰激肽原酶治疗糖尿病视网膜病变临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R774.1

基金项目:

河南省医学科技公关项目(LHGJ20191477)


Clinical Study on Liangxue Sanyu Decoction Combined with Pancreatic Kallikrein for Diabetic Retinopathy
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察凉血散瘀汤联合胰激肽原酶治疗糖尿病视网膜病变的临床疗效。方法:选取糖尿病视 网膜病变患者126 例,按随机数字表法分为西药组、中药组和联合组,每组42 例。西药组给予胰激肽原酶肠 溶片口服,中药组给予凉血散瘀汤口服,联合组给予凉血散瘀汤联合胰激肽原酶治疗。3 组连续治疗3 个月。 评价3 组治疗前后中医证候评分,检测3 组治疗前后眼动脉的收缩期峰值流速(PSV)、舒张末期血流速 度(EDV) 及血清超敏C-反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α) 水平,检 测3 组治疗前后视功能。结果:治疗后,3 组各项中医证候评分较治疗前降低(P<0.05);且联合组各项中医 证候评分低于西药组和中药组(P<0.05)。治疗后,3 组PSV、EDV 水平较治疗前升高(P<0.05);且联合组 PSV、EDV 水平高于西药组和中药组(P<0.05)。治疗后,3 组hs-CRP、IL-6、TNF-α 水平低于治疗前(P< 0.05),且联合组hs-CRP、IL-6、TNF-α 水平低于西药组和中药组(P<0.05)。治疗后,3 组最佳矫正视力、 视网膜厚度较治疗前升高,视野灰度值较治疗前降低(P<0.05);联合组最佳矫正视力、视网膜厚度高于西药 组和中药组,视野灰度值低于西药组和中药组(P<0.05)。结论:凉血散瘀汤联合胰激肽原酶治疗糖尿病视网 膜病变可以改善患者临床症状,降低机体炎症因子水平,改善眼底血流动力学和视功能。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Liangxue Sanyu Decoction combined with pancreatic kallikrein for diabetic retinopathy. Methods:A total of 126 patients with diabetic retinopathy were selected and divided into the western medicine group, the Chinese medicine group and the combination group according to the random number table method,with 42 cases in each group. The western medicine group was treated with Pancreatic Kininogenase Enteric-Coated Tablets for oral use,the Chinese medicine group was treated with Liangxue Sanyu Decoction for oral use, and the combination group was treated with Liangxue Sanyu Decoction combined with pancreatic kallikrein. The three groups were treated continuously for 3 months. The traditional Chinese medicine (TCM) syndrome scores were evaluated in the three groups before and after treatment. The peak systolic flow velocity (PSV) and end diastolic blood flow velocity (EDV) of the ophthalmic artery , as well as the levels of hypersensitive C-reactive protein (hs- CRP) , interleukin-6 (IL-6), and tumor necrosis factor - α (TNF - α) were detected before and after treatment. The visual function was detected before and after treatment in three groups. Results: After treatment, the TCM syndrome scores in the three groups were decreased when compared with those before treatment (P<0.05);the TCM syndrome scores in the combination group were lower than those in the western medicine group and the Chinese medicine group (P<0.05). After treatment,the levels of PSV and EDV in the three groups were increased when compared with those before treatment (P<0.05); the levels of PSV and EDV in the combination group were higher than those in the western medicine group and the Chinese medicine group (P<0.05). After treatment, the levels of hs-CRP,IL-6,and TNF-α in the three groups were lower than before treatment (P<0.05),and the levels of hs-CRP,IL-6,and TNF-α in the combination group were lower than those in the western medicine group and the Chinese medicine group (P<0.05). After treatment,the best corrected visual acuity and retinal thickness in the three groups were increased when compared with those before treatment,and the grayscale values of visual field were decreased when compared with those before treatment (P<0.05); the best corrected visual acuity and retinal thickness in the combination group were higher than those in the western medicine group and the Chinese medicine group, and the grayscale value of visual field was lower than those in the western medicine group and the Chinese medicine group (P<0.05). Conclusion: Liangxue Sanyu Decoction combined with pancreatic kallikrein for diabetic retinopathy can improve the clinical symptoms,reduce the levels of inflammatory factors in the body,and improve fundus hemodynamics and visual function.

    参考文献
    相似文献
    引证文献
引用本文

宋艳,王世娟,王予,杨丽,董昆仑,陈文生.凉血散瘀汤联合胰激肽原酶治疗糖尿病视网膜病变临床研究[J].新中医,2024,56(1):88-93

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-01-16
  • 出版日期:
文章二维码